LeMaitre Vascular (NASDAQ:LMAT – Get Free Report) issued an update on its third quarter 2026 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 0.660-0.710 for the period, compared to the consensus earnings per share estimate of 0.730. The company issued revenue guidance of $66.3 million-$68.3 million, compared to the consensus revenue estimate of $69.0 million. LeMaitre Vascular also updated its FY 2026 guidance to 2.840-2.940 EPS.
LeMaitre Vascular Price Performance
Shares of NASDAQ LMAT traded up $0.95 during mid-day trading on Thursday, reaching $79.95. 249,968 shares of the company traded hands, compared to its average volume of 268,212. The firm has a market cap of $1.83 billion, a PE ratio of 28.05, a price-to-earnings-growth ratio of 2.94 and a beta of 0.53. LeMaitre Vascular has a fifty-two week low of $78.65 and a fifty-two week high of $118.01. The company has a debt-to-equity ratio of 0.42, a current ratio of 14.32 and a quick ratio of 12.20. The stock has a fifty day simple moving average of $97.08 and a 200-day simple moving average of $99.99.
LeMaitre Vascular (NASDAQ:LMAT – Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The medical instruments supplier reported $0.74 earnings per share for the quarter, missing the consensus estimate of $0.81 by ($0.07). The firm had revenue of $70.38 million for the quarter, compared to the consensus estimate of $71.47 million. LeMaitre Vascular had a return on equity of 15.90% and a net margin of 25.02%.The business’s revenue for the quarter was up 9.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.60 earnings per share. Equities research analysts anticipate that LeMaitre Vascular will post 3 EPS for the current fiscal year.
LeMaitre Vascular Announces Dividend
Analyst Upgrades and Downgrades
A number of brokerages have recently issued reports on LMAT. Wells Fargo & Company dropped their price objective on LeMaitre Vascular from $104.00 to $94.00 and set an “equal weight” rating on the stock in a research note on Wednesday. Wall Street Zen downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Zacks Research downgraded LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 6th. Weiss Ratings lowered shares of LeMaitre Vascular from a “buy (b)” rating to a “buy (b-)” rating in a research note on Tuesday, June 30th. Finally, Citigroup restated a “market outperform” rating on shares of LeMaitre Vascular in a research note on Tuesday, July 21st. Four research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $110.60.
View Our Latest Stock Analysis on LMAT
Insider Buying and Selling
In other LeMaitre Vascular news, insider Trent G. Kamke sold 2,928 shares of the stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $107.00, for a total transaction of $313,296.00. Following the completion of the sale, the insider directly owned 3,749 shares in the company, valued at approximately $401,143. This trade represents a 43.85% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO George W. Lemaitre sold 27,881 shares of the business’s stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $108.69, for a total value of $3,030,385.89. Following the completion of the transaction, the chief executive officer directly owned 1,430,019 shares in the company, valued at $155,428,765.11. This represents a 1.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 7.40% of the stock is owned by company insiders.
Key LeMaitre Vascular News
Here are the key news stories impacting LeMaitre Vascular this week:
- Positive Sentiment: Second-quarter revenue increased 9.6% year over year to $70.38 million, while EPS rose to $0.74 from $0.60 a year earlier. The company also declared a quarterly dividend of $0.25 per share, equivalent to an approximately 1.1% annualized yield. LeMaitre Q2 2026 Financial Results
- Neutral Sentiment: Analyst sentiment has become more cautious. Wells Fargo lowered its price target from $104 to $94 while maintaining an Equal Weight rating, and Barrington Research downgraded the shares from Outperform to Market Perform. The average analyst view is now Hold. LeMaitre receives average Hold rating
- Negative Sentiment: Q2 EPS of $0.74 missed the $0.81 consensus estimate, and revenue of $70.38 million came in below the $71.47 million forecast. The earnings shortfall indicates that revenue growth has not translated into results as strongly as investors expected. LeMaitre Q2 earnings and revenues lag estimates
- Negative Sentiment: Management reduced its outlook: third-quarter EPS guidance of $0.66-$0.71 and revenue guidance of $66.3-$68.3 million are below consensus estimates of $0.73 and $69.0 million. Full-year EPS guidance of $2.84-$2.94 and revenue guidance of $274.3-$278.3 million also trail consensus forecasts of $3.00 and $279.9 million. LeMaitre guidance and financial results
- Negative Sentiment: The combination of missed quarterly estimates, lowered guidance, analyst downgrades and a new 12-month low is driving the bearish reaction in LMAT despite continued year-over-year growth and a strong balance-sheet profile. LeMaitre reaches new 12-month low
Hedge Funds Weigh In On LeMaitre Vascular
Several institutional investors have recently made changes to their positions in LMAT. EverSource Wealth Advisors LLC bought a new position in LeMaitre Vascular during the 2nd quarter valued at $47,000. Geneos Wealth Management Inc. raised its holdings in shares of LeMaitre Vascular by 250.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock valued at $47,000 after acquiring an additional 398 shares in the last quarter. Quarry LP boosted its position in LeMaitre Vascular by 267.2% during the third quarter. Quarry LP now owns 727 shares of the medical instruments supplier’s stock valued at $64,000 after buying an additional 529 shares during the period. Kestra Advisory Services LLC purchased a new stake in LeMaitre Vascular during the 4th quarter valued at about $68,000. Finally, Kemnay Advisory Services Inc. purchased a new stake in shares of LeMaitre Vascular during the fourth quarter valued at approximately $80,000. Institutional investors and hedge funds own 84.64% of the company’s stock.
About LeMaitre Vascular
LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.
Founded in 1983 by George D.
Featured Stories
- Five stocks we like better than LeMaitre Vascular
- Disney Sets Up for a Magical Year in 2027
- Astera Labs’ Post-Earnings Pullback May Be Last Chance to Buy Below $360
- McDonald’s Stock Sell-Off: Justified Warning or Buying Opportunity?
- Why Brown-Forman Rejected a 23% Premium Twice
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.
